These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9040014)

  • 41. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
    Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
    Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
    Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
    Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
    van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
    Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells.
    Chapatte L; Servis C; Valmori D; Burlet-Schiltz O; Dayer J; Monsarrat B; Romero P; Lévy F
    J Immunol; 2004 Nov; 173(10):6033-40. PubMed ID: 15528338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.
    Chen Q; Jackson H; Cebon J; Gibbs P; Davis ID; Trapani JA
    Melanoma Res; 2000 Feb; 10(1):16-25. PubMed ID: 10711636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.
    Tjandrawan T; Martin DM; Maeurer MJ; Castelli C; Lotze MT; Storkus WJ
    J Immunother; 1998 Mar; 21(2):149-57. PubMed ID: 9551367
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.
    Jäeger E; Bernhard H; Romero P; Ringhoffer M; Arand M; Karbach J; Ilsemann C; Hagedorn M; Knuth A
    Int J Cancer; 1996 Apr; 66(2):162-9. PubMed ID: 8603805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.
    Castelli C; Storkus WJ; Maeurer MJ; Martin DM; Huang EC; Pramanik BN; Nagabhushan TL; Parmiani G; Lotze MT
    J Exp Med; 1995 Jan; 181(1):363-8. PubMed ID: 7807017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
    J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
    Carrasco J; Van Pel A; Neyns B; Lethé B; Brasseur F; Renkvist N; van der Bruggen P; van Baren N; Paulus R; Thielemans K; Boon T; Godelaine D
    J Immunol; 2008 Mar; 180(5):3585-93. PubMed ID: 18292586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
    Loftus DJ; Squarcina P; Nielsen MB; Geisler C; Castelli C; Odum N; Appella E; Parmiani G; Rivoltini L
    Cancer Res; 1998 Jun; 58(11):2433-9. PubMed ID: 9622085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.
    Sugita S; Sagawa K; Mochizuki M; Shichijo S; Itoh K
    Int Immunol; 1996 May; 8(5):799-803. PubMed ID: 8671669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
    Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
    J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.
    Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
    Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
    Romero P; Valmori D; Pittet MJ; Zippelius A; Rimoldi D; Lévy F; Dutoit V; Ayyoub M; Rubio-Godoy V; Michielin O; Guillaume P; Batard P; Luescher IF; Lejeune F; Liénard D; Rufer N; Dietrich PY; Speiser DE; Cerottini JC
    Immunol Rev; 2002 Oct; 188():81-96. PubMed ID: 12445283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.